Sep. 2, 2015
Hutchison MediPharma has published the results of its Phase II clinical trial of fruquintinib in metastatic colorectal cancer (“mCRC”).
The top-line results demonstrated that the trial clearly succeeded in meeting the primary efficacy endpoint of progression-free survival (“PFS”).
The assessment of secondary efficacy endpoints, including objective response rate, disease control rate, and the overall survival rate, is ongoing, with all appearing in-line with expectations at the August 2015 five-month data cut-off. The adverse events demonstrated in this POC study are consistent with the known safety profile for fruquintinib without major unexpected safety issues.